Concomitant Medication Use and New-Onset Diabetes Among Medicaid Beneficiaries with Chronic Obstructive Pulmonary Disease

Mayank Ajmera, PhD,¹ Chan Shen, PhD,² and Usha Sambamoorthi, PhD³

Abstract

Use of multiple prescription medications is common among individuals with chronic obstructive pulmonary disease (COPD) because of coexisting inflammatory-related conditions. Specifically, the use of antidepressants, inhaled corticosteroids (ICSs), and statins may place individuals with COPD at high risk for new-onset diabetes. The objective was to examine the relationship between the use of antidepressants, ICSs, and statins and new-onset diabetes among Medicaid beneficiaries with COPD. This study used a retrospective longitudinal cohort design using multiple years (2005–2008) of Medicaid claims for beneficiaries with newly diagnosed COPD ($n = 15,287$), who were diabetes free at baseline. National Drug Codes were used to determine the receipt of antidepressants, ICSs, and statins, and *International Classification of Diseases, Ninth Revision, Clinical Modification* codes were used to define new-onset diabetes (250.x2). Multivariable logistic regression was used to examine the adjusted relationship between medication use and new-onset diabetes. Overall, 6.3% of the study population was diagnosed with new-onset diabetes. After controlling for baseline characteristics, individuals using ICSs (adjusted odds ratio [AOR]: 1.23; 95% confidence interval [CI]: 1.07, 1.47) or statins (AOR: 1.48; 95% CI: 1.27, 1.72) had a greater risk of new-onset diabetes compared to those not given ICSs, statins, or antidepressants. Analyses using combined medication categories revealed that adults using statins in combination with both antidepressants and ICSs, or when combined with ICS, were more likely to have new-onset diabetes. These findings indicate that multiple medication use (ICSs and statins) was associated with increased rates of new-onset diabetes. Further research is warranted to understand this association.

Introduction

CHRONIC OBSTRUCTIVE PULMONARY disease (COPD) is an inflammatory disease linked to persistent and progressive airflow limitation.^{1,2} Because COPD is no longer considered a disease exclusive to the lungs, it is increasingly being recognized as a “chronic systemic inflammatory syndrome.”³ The use of medications to treat inflammation-related multimorbidity among individuals with COPD has been increasing.⁴ A cross-sectional study using data on 126,283 individuals with COPD reported that 98% of the individuals received at least 1 prescription for “non-respiratory drugs,” with 64% cardiovascular medication and 8% depression medication use reported.⁵

Although generally regarded as safe, the adverse effects of some of these medications have raised concerns about

their safety, especially for patients with comorbid conditions. Antidepressants, inhaled corticosteroids (ICSs), and statins have been linked to new-onset diabetes.^{6–9} Several lines of evidence indicate that these medications can increase insulin resistance, decrease insulin secretion, and impact overall glucose metabolism.^{10–12} One recent literature review¹¹ concluded that an insufficient number of clinical trial investigations and observational studies have evaluated the relationship between the use of antidepressants, statins, and ICSs on new-onset diabetes in the general population.

Investigators from a large randomized controlled trial have reported that antidepressant users had a higher likelihood of developing diabetes compared to nonusers.¹³ However, further observational studies have not conclusively determined the role of antidepressants in causing new-onset

¹RTI Health Solutions, Research Triangle Park, North Carolina.

²Departments of Health Services Research and Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.

³Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, West Virginia.

diabetes. In addition, recent evidence indicates that depression symptoms, rather than antidepressant use, are associated with new-onset diabetes.¹⁴

ICSs also have been evaluated with regard to the development of type 2 diabetes among individuals with COPD.^{7,9,15} The available data indicate that ICS levels in the systemic circulation are low and, thus, may not play a major role in the risk of incident diabetes. However, evidence regarding the risk of new-onset diabetes associated with ICS use is inconclusive. In a nested case-control study using data from Quebec Health Insurance databases, Suissa et al reported that among 388,584 individuals with respiratory disease, current ICS use was associated with a 34% higher risk of incident diabetes compared to individuals who were not currently taking ICS (relative risk: 1.34; 95% confidence interval [CI]: 1.29–1.39).⁹ However, a major limitation of this study was the combined evaluation of asthma and COPD patients, because it has been established that the risk of incident diabetes is different among individuals with COPD compared to those with asthma.¹⁶ Recently, a retrospective analysis of randomized controlled trials of the ICS budesonide indicated no statistically significant difference between users and nonusers in terms of new-onset diabetes.⁷ Therefore, the relationship between ICS use and new-onset diabetes remains uncertain.

The relationship between statin use and new-onset diabetes also has not been well established. Analysis of data from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial revealed that among 17,802 individuals randomly assigned to rosuvastatin or placebo, those in the rosuvastatin group had significantly higher rates of physician-reported incident diabetes cases compared to those in the placebo group (3.0% vs. 2.4%; $P=0.01$).¹⁷ This trial included individuals with low cardiovascular risk, but high levels of inflammatory mediator C-reactive protein, a characteristic of smokers with COPD.¹⁷ On the contrary, findings from a large-scale randomized trial of pravastatin (West of Scotland Coronary Prevention Study [WOSCOPS]) suggested protective effects of pravastatin in reducing the risk of new-onset diabetes, because men aged between 45 and 64 years on pravastatin therapy had a 20% reduced hazard of developing new-onset diabetes compared to individuals on placebo (hazard ratio: 0.70; 95% CI: 0.50–0.99; $P=0.042$).¹⁸

Although inconclusive, these studies indicate plausible risks associated with medication use and new-onset diabetes. With the increasing prevalence of comorbidities among individuals with COPD and the potential use of multiple medications, it is important to assess the risk of new-onset diabetes in a real-world setting. Furthermore, it is especially important to assess the risk of new-onset diabetes among patients with COPD, as the risk of new-onset

diabetes has been found to be twice as high among individuals with COPD compared to those without COPD.¹⁶ Therefore, the primary objective of the current study was to evaluate the association between commonly used medications (antidepressants, ICSs, and statins) and new-onset diabetes among adults with newly diagnosed COPD. This study also evaluated the relationship between medication use and new-onset diabetes by statin type and determined whether the long-term use of antidepressants and statins was associated with new-onset diabetes as these medications are generally recommended for chronic condition management.

Methods

Study design

A retrospective longitudinal cohort design was used to determine the relationship between multiple medication use (antidepressants, ICSs, and statins) and new-onset diabetes. For the purpose of this study, data from administrative claims of Medicaid enrollees obtained from the Medicaid analytic extract (MAX) (2005–2008) provided by the Centers for Medicare & Medicaid Services (CMS) were used. Medicaid beneficiaries with newly-diagnosed COPD were identified between January 1, 2006 and December 31, 2007. The first date with an inpatient or outpatient claim of COPD diagnosis was considered as the index date. One year prior to the index date was considered the baseline period, and beneficiaries diagnosed with COPD or diabetes during this period were excluded from the study. New-onset diabetes was identified during the follow-up period, which was defined as 1 year after the index date. A schematic representation of the study periods is presented in Figure 1.

Data source: MAX (2005–2008)

Data from MAX from years 2005–2008 were used for this study. The files provided in the MAX administrative claim data are prepared and produced by CMS with the help of the Research and Data Assistance Center. The primary purpose of these files is to supply information regarding Medicaid beneficiary health care utilization to researchers and policy makers.

The MAX files contain person-level data, which are obtained using the Medicaid Statistical Information System through which all states administering Medicaid are required to supply information for Medicaid beneficiaries to CMS. These files provide information about beneficiaries' eligibility and their health care utilization and payment information. Several initiatives have been taken by the agencies to maintain and improve the quality of these data sets.¹⁹

FIG. 1. Schematic representation of the study design.

CMS provided separate files that were linked based on a unique identification number given to each beneficiary. These files included enrollments ("personal summaries"), inpatient and outpatient medical claims, and pharmacy claims for beneficiaries.

The personal summary files provided information on Medicaid eligibility, patient demographics (eg, age, sex, race), managed care enrollment, utilization summaries, and Medicaid payments. Three additional files (ie, Other Therapy, Inpatient, and Prescription Drug files) were used to capture information regarding beneficiaries' fee-for-service claims. The Other Therapy file contained information regarding claims for Medicaid services provided at the outpatient level such as clinic services, physician services, home health care, and laboratory services. Enrollees' information regarding services provided during hospitalizations was obtained from the Inpatient file. Information regarding pharmacy or drug services was captured from the Prescription Drug file, which included date of prescription filled, days of supply, and national drug code (NDC).

Data for beneficiaries residing in the following states were used for the study: New York, Texas, Illinois, and California. These states were chosen to capture the diverse geographic and racial/ethnic populations represented by Medicaid.

Area resource file (ARF)

In addition to the demographic characteristics and utilization variables obtained from the MAX files, each Medicaid beneficiary's contextual county level variables were determined using ARF, which is a comprehensive county-level data set compiled by the Health Resources Service Administration's Bureau of Health Professions. ARF contains more than 6000 variables that provide county information, including health facility type, number and type of health professions, resource scarcity measures, health status, economic activity, health training programs, and socioeconomic and environmental characteristics. ARF files also include county codes and descriptors that allow data linkage with several secondary data sets such as MAX. For example, the density of pulmonologists in a beneficiary's residing county was a variable obtained from ARF data. This study used county codes and state information to link MAX files with the 2005 ARF file.

Study population

Medicaid beneficiaries with newly-diagnosed COPD were identified using physician office visit claims from MAX files. Individuals with at least 1 inpatient visit or 2 outpatient visits at least 14 days apart (obtained using type of service codes) for COPD based on *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) codes for chronic bronchitis (491.xx), emphysema (492.xx), or unspecified chronic airway obstruction (496.xx) were considered to have diagnosed COPD. These diagnosis codes have been utilized in prior published research to identify COPD and to evaluate medical treatments and health care outcomes among individuals with COPD.^{20–23} Indeed, the sensitivity and specificity of using ICD-9-CM codes to identify patients with COPD have been established.^{24,25} A study conducted by Gershon et al reported that

identifying COPD using 1 or more ambulatory claims and/or hospitalizations for COPD resulted in a sensitivity of 85.0% (95% CI: 77.0 to 91.0) and a specificity of 78.4% (95% CI: 73.6 to 82.7). However, the present study requirement of 1 inpatient or 2 outpatient claims to identify individuals with COPD increased its specificity.

Other inclusion criteria included: (1) no COPD diagnoses during the baseline period; (2) no diabetes diagnoses (ICD-9-CM: 250.x2) during the baseline period; (3) 40–64 years of age (among young adults, this age group is at highest risk of COPD); (4) continuous eligibility during the baseline and follow-up periods; (5) no dual Medicaid/Medicare coverage; (6) enrolled in fee-for-service plans throughout the study observation period; (7) alive during the study observation period; and (8) use of services (inpatient or outpatient).

Dependent variable (new-onset diabetes)

A diagnosis of new-onset diabetes was determined during the follow-up period when a beneficiary had at least 1 inpatient or 2 outpatient claims for diabetes based on ICD-9-CM diagnosis (250.x2).

Independent variables

Multiple medication use. Antidepressants, ICSs, and statins were identified using NDCs recorded in pharmacy claims. Receipt of these medications was considered to be use of the medications. Statin users were defined as beneficiaries with at least 1 statin prescription during the baseline period. Antidepressant users were defined as individuals with at least 1 antidepressant prescription during the baseline period. ICS use was identified during the follow-up period because ICSs are usually prescribed to patients who have COPD, and the study population consisted of individuals with newly-diagnosed COPD who most likely had not received ICS medications before the diagnosis. Indeed, few cases with ICS use were identified during the baseline period. Medicaid beneficiaries with newly-diagnosed COPD having >120 days of supply for these medications during the baseline period were considered long-term users, while individuals with <120 days of supply were categorized as short-term users, and those with no receipt of the drugs during the baseline period were considered to be nonusers.

Other independent variables. These variables included demographic characteristics such as sex (male/female), race/ethnicity (white, African American, and other), age groups (40–49, 50–59, and 60–64 years of age), state (California, Illinois, New York, or Texas), Medicaid eligibility (income eligibility vs. medical eligibility), and clinical characteristics such as the presence of inflammation-related multimorbidity (eg, physical conditions including arthritis, cardiovascular disease, and osteoporosis; mental conditions such as depression), number of other clinical conditions, presence of serious mental illness (eg, bipolar disorder, schizophrenia), alcohol abuse, tobacco abuse, and substance abuse.

In addition, variables for access to care and socioeconomic characteristics were constructed using ARF data. These variables included quartiles for the density of the population having more than a high school education, unemployment, and poverty. The density of each county-level

characteristic was calculated by dividing the total number of individuals in the county having the characteristic by the total county population. Metro status was ascertained for each Medicaid beneficiary. Medicaid beneficiaries with COPD were categorized into metropolitan residents or non-metropolitan residents based on county-level information obtained from ARF. Other access to care variables included the density of primary care providers in the county (quartiles), density of specialist providers (quartiles), primary care shortage area (yes/no), mental health shortage area (yes/no), hospital bed density (quartiles), pulmonologist density (high/low), and cardiologist density (high/low).

Statistical analysis

Bivariate analysis. Chi-square tests of independence were used to determine subgroup differences in antidepressant, ICS, and statin use and new-onset diabetes. The results from unadjusted logistic regressions are also presented for a better understanding of the bivariate relationships between specific medication use categories and new-onset diabetes.

Multivariate analysis. Multivariable logistic regression was used to examine the relationship between antidepressant, ICS, and statin use and new-onset diabetes after controlling for the comprehensive set of independent variables as described. SAS v 9.3 (SAS Institute, Inc., Cary, NC) was used for the analyses.

Results

Table 1 presents a description of the study cohort and personal, as well as county-level, characteristics. The table also presents bivariate differences in medication use by beneficiary characteristics. Overall, 6.3% of the Medicaid beneficiaries (967 out of 15,287 individuals) with newly-diagnosed COPD were diagnosed with new-onset diabetes during the follow-up period. In the study population, a total of 7313 individuals (47.8%) received antidepressants, 3720 (24.3%) received statins, and 6554 (41.4%) received ICS. Chi-square tests showed that women were more likely to have medication use for all 3 medication groups (antidepressant, statin, and ICS). Similarly, white people were more likely to have medications than African Americans. A higher number of other clinical conditions and the presence of serious mental illness also were significantly associated with higher medication use.

Table 2 describes the unadjusted and adjusted relationships between antidepressant, statin, or ICS use and new-onset diabetes in individuals with newly-diagnosed COPD. Rates of new-onset diabetes were not significantly different between antidepressant users and nonusers (6.5% vs. 6.2%). However, beneficiaries with statin use had significantly higher rates of new-onset diabetes compared to those without statin use ($P < 0.001$). Similarly, individuals with ICS use had significantly higher rates of new-onset diabetes compared to those without ICS use ($P < 0.001$). After controlling for baseline characteristics (eg, age, inflammation-related multimorbidity, and primary care provider density), beneficiaries who received statins or ICSs were 48% and 23% more likely to have new-onset diabetes compared with their counterparts who did not receive these medications.

To assess the relationship between combined medication categories and new-onset diabetes, variables were created

with the following categories: (1) all 3 medications; (2) antidepressants and statins; (3) antidepressants and ICSs; (4) statins and ICSs; (5) statins only; (6) ICSs only; and (7) none of these medications. Findings from bivariate and multivariate analyses with combined medication categories are presented in Table 3. Individuals who were given all 3 medications were significantly more likely to have new-onset diabetes (adjusted odds ratio: 1.56; 95% CI: 1.18, 2.05) compared to those who were not given any of these 3 medications. Similarly, individuals who used statins in combination with ICSs were more likely to have new-onset diabetes compared with those without any medications.

As use of statins was associated with risk of developing new-onset diabetes, we further compared the certain baseline characteristics of patients with and without statin use that may have confounded the relationship between statin use, and new-onset diabetes. Results from these analyses are presented in Supplementary Table S1 (supplementary material is available in the online article at www.liebertpub.com/pop).

Discussion

This study used a retrospective longitudinal dynamic cohort design to examine the relationship between commonly used medications such as antidepressants, ICSs, and statins and new-onset diabetes among Medicaid beneficiaries with newly-diagnosed COPD. Medicaid claim data from multiple years (2005–2008) were used for the analysis. To the best of the authors' knowledge, this is the first observational study to examine this relationship using Medicaid claim data for nonelderly adults with newly-diagnosed COPD. Therefore, it is not feasible to compare these results with those of prior studies given the differences in patient demographic and clinical data.

Because statins are being investigated as novel therapeutic agents among individuals with COPD, this study examined the relationship between statin use and new-onset diabetes. The data revealed that adults who had used statins were more likely to have new-onset diabetes compared with those not taking statins. Previous randomized controlled trials and meta-analyses have yielded conflicting results on statin use and new-onset diabetes. A meta-analysis performed with data from the WOSCOPS study has shown that statin use did not increase the risk of new-onset diabetes.²⁶ However, other studies have reported that statin use is associated with a greater risk of new-onset diabetes.^{8,27,28} Therefore, additional research is required to determine the safety of statin use in high-risk populations, such as in individuals with COPD.

The significant association between the use of ICS and new-onset diabetes found is consistent with the results from a retrospective cohort study using the Quebec Health Insurance database, which included patients with any respiratory disease.⁹ The present analyses also showed that when considering multiple combinations of medications, the combined use of statins and ICSs with or without antidepressants was significantly associated with a higher likelihood of new-onset diabetes.

After controlling for baseline characteristics, no statistically significant association was observed between only antidepressant use and new-onset diabetes. These results are consistent with studies that used data from the general population (ie, not specific to individuals with COPD). For example, no significant association between antidepressant use and new-onset diabetes was found in several previous studies.^{14,29,30} Recently, a review

TABLE 1. NUMBERS & PERCENTAGES OF MEDICATION USE AMONG MEDICAID BENEFICIARIES
WITH NEWLY-DIAGNOSED CHRONIC OBSTRUCTIVE PULMONARY DISEASE, MEDICAID ANALYTIC EXTRACT, 2005–2008

	<i>Any AD use</i>			<i>Any statin use</i>			<i>Any ICS use</i>		
	n	Row %	Sig.	n	Row %	Sig.	n	Row %	Sig.
Total	7313	47.8		3720	24.3		6554	41.4	
Cohort						*			
2005–2007	4148	48.0		2041	23.6		3746	43.4	
2006–2008	3165	47.6		1679	25.3		2808	42.2	
Sex			***			***			***
Women	4853	54.6		2299	25.9		4209	47.4	
Men	2460	38.4		1421	22.2		2345	36.6	
Race/ethnicity			***			***			***
White	4121	53.9		2005	26.2		3372	44.1	
African American	1527	37.6		755	18.6		1645	40.5	
Others	1665	46.6		960	26.9		1537	43.0	
Age (in years)			***			***			
40–49	2787	51.9		934	17.4		2262	42.1	
50–59	3470	47.6		1883	25.8		3129	42.9	
60–64	1056	40.3		903	34.4		1163	44.4	
State			***			***			***
California	4055	48.0		2100	24.9		3481	41.2	
Illinois	1548	48.0		764	23.7		1455	45.1	
New York	1104	51.8		566	26.5		1188	55.7	
Texas	606	40.8		290	19.5		430	29.0	
Income eligibility			**			***			*
Yes	6753	48.2		3471	24.8		5976	42.7	
No	560	43.7		249	19.4		578	45.1	
Medical eligibility						***			
Yes	814	48.1		338	20.0		740	43.7	
No	6499	47.8		3382	24.9		5814	42.8	
Inflammation-related multimorbidity			***			***			
Physical only	2601	40.0		2087	32.1		2787	42.8	
Mental only	1011	78.8		184	14.3		567	44.2	
Both	2245	81.4		846	30.7		1216	44.1	
None	1456	30.7		603	12.7		1984	41.9	
Number of other clinical conditions			***			***			***
None	135	30.6		61	13.8		143	32.4	
1–3	1209	37.9		641	20.1		1244	39.0	
4–6	1618	42.8		894	23.6		1579	41.7	
>6	4351	55.3		2124	27.0		3588	45.6	
Serious mental illness			***			***			***
Yes	2514	62.2		856	21.2		1403	34.7	
No	4799	42.7		2864	25.5		5151	45.8	
Alcohol abuse			***			***			***
Yes	828	53.4		217	14.0		569	36.7	
No	6485	47.2		3503	25.5		5985	43.6	
Substance abuse			***			***			
Yes	1286	57.3		295	13.1		950	42.3	
No	6027	46.2		3425	26.3		5604	43.0	
Tobacco use			***			***			
Yes	1176	56.7		439	21.2		922	44.5	
No	6137	46.4		3281	24.8		5632	42.6	
Polypharmacy			***			***			***
Yes	4559	65.2		2629	37.6		3720	53.2	
No	2754	33.2		1091	13.1		2834	34.2	
ARF variables (county level)									
Above HS education density			***			***			***
Q1	3621	45.6		1999	25.2		3239	40.8	
Q2	1107	50.2		552	25.0		943	42.7	
Q3	1593	50.1		767	24.1		1449	45.6	
Q4	992	50.5		402	20.5		923	47.0	

(continued)

TABLE 1. (CONTINUED)

	<i>Any AD use</i>			<i>Any statin use</i>			<i>Any ICS use</i>		
	n	Row %	Sig.	n	Row %	Sig.	n	Row %	Sig.
Unemployment density			***			*			***
Q1	5263	46.5		2734	24.1		4683	41.3	
Q2	1068	51.1		541	25.9		964	46.1	
Q3	741	52.1		318	22.4		686	48.3	
Q4	241	53.8		127	28.3		221	49.3	
Poverty density			**			**			***
Q1	647	50.5		270	21.1		585	45.7	
Q2	1080	48.9		501	22.7		953	43.2	
Q3	1409	49.8		689	24.4		1286	45.5	
Q4	4177	46.6		2260	25.2		3730	41.6	
Metro			***						
Yes	6222	47.0		3202	24.2		5673	42.9	
No	1091	53.3		518	25.3		881	43.0	
PCP shortage						*			
Yes	7003	47.8		3586	24.5		6288	42.9	
No	310	49.5		134	21.4		266	42.5	
Mental health specialist shortage			***						***
Yes	6457	47.3		3313	24.3		5750	42.1	
No	856	52.1		407	24.8		804	48.9	
PCP density			***						***
Q1	321	50.8		161	25.5		326	51.6	
Q2	1335	51.7		674	26.1		1147	44.4	
Q3	1136	51.8		527	24.0		1025	46.7	
Q4	4521	45.8		2358	23.9		4056	41.1	
Hospital bed density			***			**			***
Q1	432	53.9		203	25.3		401	50.1	
Q2	1230	49.2		560	22.4		1092	43.6	
Q3	3983	46.4		2168	25.2		3440	40.0	
Q4	1668	49.2		789	23.3		1621	47.8	
Psychiatric hospital			***						
Yes	4497	46.2		2395	24.6		4132	42.5	
No	2816	50.7		1325	23.9		2422	43.6	
Pulmonologist density			***			*			***
High	4913	45.9		2546	23.8		4346	40.6	
Low	2400	52.3		1174	25.6		2208	48.1	
Cardiologist density			***						***
High	4601	46.1		2401	24.1		4094	41.0	
Low	2712	51.1		1319	24.9		2460	46.4	

Based on 15,287 Medicaid beneficiaries with newly diagnosed COPD and who were diabetes free during the baseline period obtained from Medicaid analytic extract files observed during 2005–2008. Asterisks represent significant group differences in beneficiary characteristics by medication use obtained from chi-square test.

*** $P < 0.001$; ** $0.001 \leq P < 0.01$; * $0.01 \leq P < 0.05$.

AD, antidepressant; ARF, area resource file; COPD, chronic obstructive pulmonary disease; HS, high school; ICS, inhaled corticosteroid; PCP, primary care provider; Q, quarter; Sig., significance.

on glucose metabolism and antidepressant medications suggested that the relationship between antidepressant use and new-onset diabetes may vary by type of antidepressant. The deleterious effects of nonadrenergic antidepressants are thought to be negated by the beneficial effects of monoamine oxidase inhibitors with regard to glucose metabolism.³¹ However, monoamine oxidase inhibitors are an older class of antidepressants and are not commonly prescribed. Therefore, further analyses are required to determine whether the type of antidepressant used influences new-onset diabetes. Moreover, randomized controlled trials among individuals with COPD are warranted to determine whether treatment with antidepressants is a factor that affects new-onset diabetes.

Overall, the findings of the present study indicate that, after controlling for baseline characteristics and selection bias, the use of statins and ICSs was associated with increased risk of new-onset diabetes compared to individuals who did not receive any of the medications considered (statins, ICSs, and antidepressants). With the prevalence of diabetes increasing, it is important to recognize the greater risk of developing new-onset diabetes among individuals with COPD who take medications. Continuous glucose monitoring for COPD patients may be needed. Long-term observational studies and randomized controlled trials should be conducted in the future to evaluate the safety of the aforementioned medications in individuals with COPD.

TABLE 2. NUMBERS, PERCENTAGES, UNADJUSTED & ADJUSTED ODDS RATIO, AND 95% CONFIDENCE INTERVALS FROM LOGISTIC REGRESSIONS ON NEW-ONSET DIABETES AMONG MEDICAID BENEFICIARIES WITH NEWLY-DIAGNOSED CHRONIC OBSTRUCTIVE PULMONARY DISEASE, MEDICAID ANALYTIC EXTRACT, 2005–2008

<i>New-onset diabetes</i>								
	n	Row %	OR	95% CI	Sig.	AOR	95% CI	Sig.
Total	967	6.3						
Any antidepressant use								
Yes	475	6.5	1.06	0.93, 1.20		0.91	0.78, 1.06	
No	492	6.2						
Any ICS use								
Yes	488	7.4	1.39	1.22, 1.58	***	1.23	1.07, 1.47	**
No	479	5.5						
Any statin use								
Yes	344	9.2	1.79	1.56, 2.05	***	1.48	1.27, 1.72	***
No	623	5.4						

Based on 15,287 Medicaid beneficiaries with newly diagnosed COPD who were diabetes free during the baseline period obtained from Medicaid analytic extract files observed during 2005–2008. Asterisks represent significant group differences in likelihood of new-onset diabetes by antidepressant, ICS, and statin use compared to the reference group (none) obtained from unadjusted and adjusted logistic regression analyses.

Adjusted logistic regressions controlled for cohort year, sex, race, age, state, poverty eligibility, inflammation-related multimorbidity, number of other clinical conditions, serious mental illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, and county-level variables, including: above high school education density (quartiles), unemployment density (quartiles), poverty density (quartiles), metro status, primary care shortage area, mental health shortage area, primary care provider density (quartiles), hospital bed density (quartiles), psychiatric hospital, pulmonologist density, and cardiologist density in addition to medication use.

*** $P < 0.001$; ** $0.001 \leq P < 0.01$; * $0.01 \leq P < 0.05$.

AOR, adjusted odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; OR, odds ratio; Sig., significance.

and other specialized patient populations susceptible to new-onset diabetes.

Strengths and limitations

This study has several strengths, including the use of large data sets to gain a comprehensive understanding of

whether multiple medication types were associated with new-onset diabetes in COPD patients. The use of Medicaid claim, data enabled the tracking of individuals for more than 2 years and the adoption of a longitudinal design. Clinical diagnoses with ICD-9-CM codes provided information on medical conditions. Prescription drug claims facilitated the

TABLE 3. NUMBERS, PERCENTAGES, UNADJUSTED & ADJUSTED ODDS RATIOS, AND 95% CONFIDENCE INTERVALS FROM LOGISTIC REGRESSIONS ON NEW-ONSET DIABETES MEDICAID BENEFICIARIES WITH NEWLY-DIAGNOSED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COMBINED MEDICATION USE CATEGORIES), MEDICAID ANALYTIC EXTRACT, 2005–2008

<i>New-onset diabetes</i>								
	n	Row%	OR	95% CI	Sig.	AOR	95% CI	Sig.
Total	967	6.3						
Medication use categories								
All 3	107	10.0	2.17	1.69, 2.77	***	1.56	1.18, 2.05	**
AD/statin	79	7.9	1.67	1.27, 2.19	***	1.29	0.96, 1.74	
AD/ICS	149	6.3	1.31	1.05, 1.63	*	1.09	0.86, 1.39	
Statin/ICS	90	12.4	2.74	2.11, 3.57	***	2.06	1.56, 2.72	***
AD only	140	4.9	0.99	0.79, 1.24		0.90	0.71, 1.14	
Statin only	68	7.3	1.54	1.15, 2.04	**	1.26	0.94, 1.70	
ICS only	142	5.9	1.22	0.98, 1.53		1.11	0.88, 1.39	
None	192	4.9		Reference			Reference	

Based on 15,287 Medicaid beneficiaries with newly diagnosed COPD who were diabetes free during the baseline period obtained from Medicaid analytic extract files observed during 2005–2008. Asterisks represent significant group differences in likelihood of new-onset diabetes by multiple medication use categories compared to the reference group (none) obtained from unadjusted and adjusted logistic regression analyses.

Adjusted logistic regressions controlled for cohort year, sex, race, age, state, poverty eligibility, inflammation-related multimorbidity, number of other clinical conditions, serious mental illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, and county-level variables, including: above high school education density (quartiles), unemployment density (quartiles), poverty density (quartiles), metro status, primary care shortage area, mental health shortage area, primary care provider density (quartiles), hospital bed density (quartiles), psychiatric hospital, pulmonologist density, and cardiologist density in addition to medication use.

*** $P < 0.001$; ** $0.001 \leq P < 0.01$; * $0.01 \leq P < 0.05$.

AD, antidepressant; AOR, adjusted odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; OR, odds ratio; Sig., significance.

identification of specific drugs and the precise time during which they were prescribed, enabling the calculation of the duration of medication use. This study also used statistical tools that controlled for selection bias related to unobserved characteristics.

A limitation of this study is a potential lack of generalizability, as only fee-for-service claims of Medicaid beneficiaries living in 4 states were included. However, these states were among the largest states in terms of the number of Medicaid enrollees and include very diverse geographic and racial/ethnic populations. There have been many studies using Medicaid data from 1 or more states.^{32–34} In terms of medication use, the study observations were restricted to specific classes of medications because taking into account all medication classes would be an impracticable task. In addition, the use of prescription drug claims has an inherent limitation of not being able to determine the actual use of these medications. However, using claims to identify the use of medications has been very well accepted in the literature. Finally, certain clinical data, such as cholesterol and baseline blood glucose levels, as well as body mass index, were unavailable and limited the ability to control for other important factors that may have been useful predictors of new-onset diabetes.

Conclusions

Despite these limitations, the current study is the first real-world observational study to examine the relationship between commonly used medications, such as antidepressants, ICSs, and statins, and new-onset diabetes among Medicaid beneficiaries with newly-diagnosed COPD. Although there has been documented evidence of increased risk of new-onset diabetes related to obesity, physical inactivity, unhealthy diet, and smoking,^{16,35} the current study highlighted additional risk factors—namely, statins and ICSs that are prescribed for treatment of COPD and allied comorbid conditions. The study finding suggests that patient education and counseling regarding the risk and benefits of statins and ICSs have to be provided for patients with COPD. In addition, health care providers must reinforce the importance of maintaining normal weight, healthy diet, physical activity, and smoking cessation in minimizing the risk of new-onset diabetes among individuals with COPD who are on statins for the management of their cardiovascular health.

Author Disclosure Statement

Drs. Ajmera, Shen, and Sambamoorthi declared that they have no conflicts of interest. The authors received no financial support for the research, authorship, and/or publication of this article.

References

- Górska K, Maskey-Warzechowska M, Krenke R. Airway inflammation in chronic obstructive pulmonary disease. *Curr Opin Pulm Med* 2010;16:89–96.
- Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007;176:532–555.
- Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? *Lancet* 2007;370:797–799.
- Lehr PS. Global markets for asthma and COPD drugs. Wellesley, MA: BCC Research LLC, 2012.
- Anecchino C, Rossi E, Fanizza C, De Rosa M, Tognoni G, Romero M. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. *Int J Chron Obstruct Pulmon Dis* 2007;2:567–574.
- Bhattacharjee S, Bhattacharya R, Kelley GA, Sambamoorthi U. Antidepressant use and new-onset diabetes: a systematic review and meta-analysis. *Diabetes Metab Res Rev* 2013;29:273–284.
- O'Byrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. *Respir Med* 2012;106:1487–1493.
- Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010;375:735–742.
- Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. *Am J Med* 2010;123:1001–1006.
- Carvalho F, Barros D, Silva J, et al. Hyperglycemia induced by acute central fluoxetine administration: role of the central CRH system and 5-HT₃ receptors. *Neuropeptides* 2004;38:98–105.
- Colbert JD, Stone JA. Statin use and the risk of incident diabetes mellitus: a review of the literature. *Can J Cardiol* 2012;28:581–589.
- Nielsen MF, Caumo A, Chandramouli V, et al. Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. *Am J Physiol Endocrinol Metab* 2004;286:E102–E110.
- Rubin RR, Ma Y, Marrero DG, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. *Diabetes Care* 2008;31:420–426.
- Sambamoorthi U, Ma Y, Findley PA, Rust G. Antidepressant use, depression, and new onset diabetes among elderly medicare beneficiaries. *J Diabetes* 2013;5:327–335.
- Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. *J Gen Intern Med* 2002;17:717–720.
- Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. *Diabetes Care* 2004;27:2478–2484.
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359:2195–2207.
- Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. *Circulation* 2001;103:357–362.
- Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). *Med Care* 2007;45:1216–1220.
- Ajmera M, Raval AD, Shen C, Sambamoorthi U. Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis. *Int J Chron Obstruct Pulmon Dis* 2014;9:339–348.
- Ajmera M, Shen C, Pan X, Findley PA, Rust G, Sambamoorthi U. Inhaled anticholinergic use and all-cause mor-

- tality among elderly Medicare beneficiaries with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2013;8:287–294.
22. Halpern R, Baker CL, Su J, et al. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. *Patient Preference Adherence* 2011;5:375–388.
 23. Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. *Int J Chron Obstruct Pulmon Dis* 2012;7:1–9.
 24. Cooke CR, Joo MJ, Anderson SM, et al. The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. *BMC Health Serv Res* 2011;11:37–46.
 25. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. *COPD* 2009;6:388–394.
 26. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. *Diabetes Care* 2009;32:1924–1929.
 27. Hennings JM, Schaaf L, Fulda S. Glucose metabolism and antidepressant medication. *Curr Pharm Des* 2012;18:5900–5919.
 28. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM* 2011;104:109–124.
 29. Wilkins TL, Sambamoorthi U. Antidepressant use, depression, lifestyle factors, and new-onset diabetes. *Int Clin Psychopharmacol* 2011;26:159–168.
 30. Bhattacharya R, Ajmera M, Bhattacharjee S, Sambamoorthi U. Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults. *Diabetes Res Clin Pract* 2014;105:251–260.
 31. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA* 2011;305:2556–2564.
 32. Prince JD, Akincigil A, Hoover DR, Walkup JT, Bilder S, Crystal S. Substance abuse and hospitalization for mood disorder among Medicaid beneficiaries. *Am J Public Health* 2009;99:160–167.
 33. Iezzoni LI. Using administrative data to study persons with disabilities. *Milbank Q* 2002;80:347–379.
 34. Riley GF. Administrative and claims records as sources of health care cost data. *Med Care* 2009;47 suppl 1:S51–S55.
 35. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Risk factors for type 2 diabetes. www.niddk.nih.gov/health-information/health-communication-programs/ndep/am-i-at-risk/diabetes-risk-factors/Pages/diabetesriskfactors.aspx Accessed June 23, 2016.

Address correspondence to:
Chan Shen, PhD

Departments of Health Services Research and Biostatistics
University of Texas MD Anderson Cancer Center
1400 Pressler Street
Houston, TX 77030

E-mail: cshen@mdanderson.org